First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)

Spreafico, A.; Heirali, A.A.; Araujo, D.V.; Tan, T.J.; Oliva, M.; Schneeberger, P.H.H.; Chen, B.; Wong, M.K.; Stayner, L.-A.; Hansen, A.R.; Saibil, S.D.; Wang, B.X.; Cochrane, K.; Sherriff, K.; Allen-Vercoe, E.; Xu, W.; Siu, L.L.; Coburn, B.

doi:10.1016/j.annonc.2023.02.011

First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)

BACKGROUND The intestinal microbiome has been associated with response to immune checkpoint inhibitors (ICI) in humans, and causally implicated in ICI responsiveness in animal models. Two recent human trials demonstrated that fecal microbiota transplant (FMT) from ICI responders can rescue ICI re…